Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Mollie Leoni, ...
Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications - - Deal terms align shareholders' inter ...
Dorocubicel is under clinical development by ExCellThera and currently in Phase II for Blood Cancer. According to GlobalData, Phase II drugs for Blood Cancer have a 34% phase transition success rate ...
Tumor cells circulating in the blood are the 'germ cells' of breast cancer metastases. They are very rare and could not be propagated in the culture dish until now, which made research into therapy ...
Tumor cells circulating in the blood are the "germ cells" of breast cancer metastases. They are very rare and could not be propagated in the culture dish until now, which made research into therapy ...